Skip to main content

Table 3 Univariate and multivariate Cox proportional hazards models for CDI post-allogeneic HCT, per transplanting hospital

From: Evaluating risk factors for Clostridium difficile infection in adult and pediatric hematopoietic cell transplant recipients

 

Pediatric transplants (n =192)

Adult transplants (n =990)

 

Univariate

Multivariate

Univariate

Multivariate

Variable

HR

p

HR

p

HR

p

HR

p

Age group (yr)

 

.5

      

1–5

Ref.

 

 

 

 

6–10

0.8

       

11–15

1.5

       

16+

0.9

       

<60

   

Ref.

.04

 

60+

    

0.6

   

Year of transplant

 

.03

 

.03

 

.42

  

2008

Ref.

 

Ref.

 

Ref.

   

2009

0.9

 

0.9

 

1.5

 

 

2010

1.6

 

1.6

 

1.6

   

2011

1.7

 

1.7

 

1

   

2012

4

 

4

 

1.5

   

Stem cell source

 

.32

   

.13

  

Bone marrow

Ref.

 

 

Ref.

 

 

PBSC

1.9

   

0.6

   

Cord blood

1.2

   

0.8

   

GVHD prophylaxis

 

.06

   

.13

  

CSP or FK506, with MTX

Ref.

 

 

Ref.

 

 

MMF regimen

0.9

   

0.7

   

Other/none

3.1

   

1.1

   

Conditioning regimen

 

.57

   

.005

 

.005

Nonmyeloablative

Ref.

 

 

Ref.

 

Ref.

 

Myeloablative

1.5

   

1.8

 

1.8

 

Overall GVHD a

 

.24

   

.34

  

Grades 0–I

Ref.

 

 

Ref.

 

 

Grades II–IV

1.1

   

1.3

   

Gut GVHD a

 

.6

   

.83

  

Grades 0–I

Ref.

 

 

Ref.

 

 

Grades II–IV

0.6

   

0.9

   

Inpatient acquisition b

1.7

.02

 

2.1

.12

 
  1. Abbreviations: PBSC (peripheral blood stem cells), GVHD (graft-versus-host disease), CSP (cyclosporine), FK506 (tacrolimus), MTX (methotrexate), MMF (mycophenolate mofetil), a GVHD onset modeled as time-dependent
  2. bdefined as inpatient stay within 3 days prior to the day of observation